Anti-Cd47 Antibodies

The mechanism of action of anti-CD47 antibodies & where these may fit in the MDS treatment landscape

VJHemOnc – Video Journal of Hematology & HemOnc

Anti-CD47 antibodies & azacitidine for AML and MDS

VJHemOnc – Video Journal of Hematology & HemOnc

Anti-CD47 antibodies for complex karyotype AML

VJHemOnc – Video Journal of Hematology & HemOnc

Preliminary results of lemzoparlimab, an anti-CD47 antibody in R/R NHL

VJHemOnc – Video Journal of Hematology & HemOnc

David Sallman, MD, elaborates on the first-in-class anti-CD47 antibody magrolimab

CD47 Discovery: Flipping the Script on Cancer | Stanford Cancer Institute

Stanford Cancer Institute

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

CD47-Blocking Agents: An Emerging Checkpoint Inhibitor Approach in Hematologic Malignancies

Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?

Advances in immunotherapy for MDS: anti-TIM-3 & anti-CD47 antibodies and small molecule inhibitors

VJHemOnc – Video Journal of Hematology & HemOnc

Updates to Protocols and Procedures for Anti-CD47 Agents in Clinical Laboratories

SIRPα/CD47: Don’t Eat Me!

Promega Corporation

Dose escalation of the anti-CD47 TTI-622 in NHL

VJHemOnc – Video Journal of Hematology & HemOnc

Anti-CD47 Antibody Therapy

Apoorva Iyengar

CD47 Antibody treatment shrinks or eliminates human cancer tumors in mice

institutesofmedicine

063CE: Anti-CD47 Testing Interference with Connie Westhoff

Blood Bank Guy (D. Joe Chaffin MD)

CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc

Immune Checkpoint Inhibition in Myeloid Malignancies

Yale Cancer Center

Deciphering the Clinical Clues: Updates to Protocols and Procedures for Anti-CD47 Agents

Targeting CD47 in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc